This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
Nov 13, 2017At-home collection, one-day fecal immunochemical test that meets American Cancer Society guidelines and HEDIS quality measures for lower gastrointestinal bleeding screening programs
Bridgewater, N.J., and Secaucus, N.J., Nov. 13, 2017 -- Clinical Genomics, a private company and Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services,...
Nov 1, 2017Quest Diagnostics to Present New Insights in Autoimmune Disease at the 2017 American College of Rheumatology MeetingFive Presentations Show the Clinical Value of Diagnostic Innovations for Assessing Prevalent Autoimmune Diseases, Including Rheumatoid Arthritis and Lupus
Secaucus, NJ, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today that it will present results of...
Oct 30, 2017Transaction Expands Access to Innovative, High-Value Diagnostic Information Services in Southern California
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has acquired certain assets of California Laboratory Associates (CLA), a clinical...
Oct 19, 2017Quest Diagnostics Reports Third Quarter 2017 Financial Results, Updates 2017 Financial Guidance and Reaffirms Long Term Outlook- Third quarter revenues of $1.93 billion, up 2.4% versus 2016.
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the third quarter ended September 30, 2017. "We...
Oct 18, 2017Quest Diagnostics to Acquire Cleveland HeartLab and Form Strategic Collaboration with Cleveland Clinic- Cleveland HeartLab to be the base for Quest's first national center of excellence in cardiometabolic disorders, with a focus on services that help patients and physicians nationwide identify hidden risks of heart disease
Quest Diagnostics (NYSE: DGX) today announced it has formed a definitive agreement to acquire Cleveland HeartLab, a leader in innovative diagnostic services for managing cardiovascular disease,...